CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

208194Orig1s000

PHARMACOLOGY REVIEW(S)



MEMORANDUM

Date: November 10, 2015

From: Christopher M. Sheth, PhD

Pharmacology/Toxicology Supervisor

Division of Hematology Oncology Toxicology (DHOT) Office of Hematology and Oncology Products (OHOP)

Re: Approvability for Pharmacology and Toxicology

NDA: 208194

Drug: Bendamustine hydrochloride

Indications: Chronic lymphocytic leukemia and B cell non-Hodgkin lymphoma

Applicant: Eagle Pharmaceuticals, Inc.

I have examined the pharmacology/toxicology supporting review for bendamustine HCl conducted by Dr. Manning. I concur with Dr. Manning's conclusion that bendamustine HCl may be approved for the proposed indication.



This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.
/s/
CHRISTOPHER M SHETH 11/10/2015



DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH

PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION

Application number: NDA 208194

Supporting document/s: 1

Applicant's letter date: February 12, 2015

CDER stamp date: February 13, 2015

Product: Bendamustine hydrochloride (HCI)

Indication: Chronic lymphocytic leukemia (CLL)

B cell non-Hodgkin lymphoma (NHL)

Applicant: Eagle Pharmaceuticals, Inc (EPI)

Review Division: Division of Hematology Oncology Toxicology

(DHOT) for Division of Hematology Products

(DHP)

Reviewer: Michael L Manning, PhD (DHOT)

Supervisor/Team Leader: Christopher M Sheth, PhD (DHOT)

Division Director: John Leighton, PhD, DABT (DHOT)

Ann Farrell, MD (DHP)

Project Manager: Laura Wall, MS, APHN, OCN

Disclaimer

Except as specifically identified, all data and information discussed below and necessary for approval of NDA 208194 are owned by EPI or are data for which EPI has obtained a written right of reference. Any information or data necessary for approval of NDA 208194 that EPI does not own or have a written right to reference constitutes one of the following: (1) published literature, or (2) a prior FDA finding of safety or effectiveness for a listed drug, as reflected in the drug's approved labeling. Any data or information described or referenced below from reviews or publicly available summaries of a previously approved application is for descriptive purposes only and is not relied upon for approval of NDA 208194.



TABLE OF CONTENTS

1	EX	ECUTIVE SUMMARY	4
	1.1 1.2 1.3	Introduction	4
2	DR	UG INFORMATION	5
	2.1 2.2 2.3 2.4 2.5 2.6	DRUG RELEVANT INDS, NDAS, BLAS AND DMFS DRUG FORMULATION COMMENTS ON NOVEL EXCIPIENTS COMMENTS ON IMPURITIES/DEGRADANTS OF CONCERN PROPOSED CLINICAL POPULATION AND DOSING REGIMEN	5 6 7
	2.7	REGULATORY BACKGROUND	
3	ST	UDIES SUBMITTED	8
	3.1 3.2 3.3	Studies Reviewed Studies Not Reviewed Previous Reviews Referenced	8
4	PH	ARMACOLOGY	9
5	PH	ARMACOKINETICS/ADME/TOXICOKINETICS	9
6	GE	NERAL TOXICOLOGY	9
7	GE	NETIC TOXICOLOGY	9
8	CA	RCINOGENICITY	9
9		PRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY	
1(SPECIAL TOXICOLOGY STUDIES	
1		NTEGRATED SUMMARY AND SAFETY EVALUATION	
12	2 <i>F</i>	APPENDIX/ATTACHMENTS	12



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

